Ask the Experts
Meet our Expert: Dr. Stuart Mair
Dr. Stuart Mair: Global VP, Medical, Early Development
Dr. Stuart (Stu) Mair has over 16 years of experience delivering exploratory clinical studies in the contract research organization (CRO) industry. He has delivered over 100 first-in-human (FIH) studies and is an expert in the design and implementation of exploratory clinical trials from FIH to proof of concept (POC) in patient groups with pharmacodynamic (PD) biomarkers. Stuart has advised clients on multiple study types, from simple pharmacokinetic (PK), bioequivalence (BE), and characterization studies to complex and flexible designs with multiple portions delivered under a single protocol.
Prior to joining Quotient Sciences, Stuart was the Medical Director at Charles River Laboratories. He holds a MBChB (Bachelor of Medicine and Bachelor of Surgery) degree and DRCOG (Diploma of the Royal College of Obstetricians and Gynaecologists), DCPSA (Diploma in Clinical Pharmacology of the Society of Apothecaries), and MFPM (Membership of the Faculty of Pharmaceutical Medicine) credentials from the University of Aberdeen in the UK.
Topics of interest
Connect on LinkedIn
Ask a question
If you have a question for Dr. Stuart Mair, please fill out the form below.
Featured Publication
"CC‑99677, a novel, oral, selective covalent MK2 inhibitor, sustainably reduces pro‑inflammatory cytokine production"
Spondyloarthritis is a type of inflammatory disease that impacts the vertebral column. It comprises a group of inflammatory rheumatic diseases that is characterized by spinal and peripheral joint oligoarthritis and enthesitis and may be associated with mucocutaneous, ocular, and/or cardiac comorbidities.
There is an unmet need when it comes to therapies that can address both disease-related parameters and radiographic progression of spondyloarthritis.
Dr. Stuart Mair contributed to a peer-reviewed scientific article in Arthritis Research & Therapy with BioMed Central (BMC). The study, led by Bristol Meyers Squibb and its researchers, reviews a Phase I clinical trial to assess the safety and tolerability of the MK2 inhibitor CC-99677, a potential new treatment for ankylosing spondylitis (AS) and related conditions.